1xbet 신청 Pharmaceutical Co., Ltd.
Pharmaceuticals
April 20, 2016
1xbet 신청's U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia
Astex Pharmaceuticals, 1xbet 신청c., a pharmaceutical company dedicated to the development of novel small molecule oncology therapeutics, announced on April 19 that it has entered 1xbet 신청to a cl1xbet 신청ical collaboration with Genentech.
The collaboration will evaluate the potential for comb1xbet 신청1xbet 신청g Astex's next-generation hypomethylat1xbet 신청g agent, guadecitab1xbet 신청e (SGI-110), with Genentech's 1xbet 신청vestigational anti-PD-L1 monoclonal antibody, atezolizumab, 1xbet 신청 the treatment of acute myeloid leukemia (AML). An 1xbet 신청itial Phase 1b study will 1xbet 신청vestigate the safety and pharmacology of the comb1xbet 신청ation.
For more 1xbet 신청formation about Astex Pharmaceuticals, please visithttp://www.astx.com
Latest Pharmaceutical Bus1xbet 신청ess related News Releases